سعر نيكسيرزوفا 5مجم 14 قرص 2026

Nexirozova 5 mg film-coated tablets (Zeta Pharma, Egypt): oral rosuvastatin (HMG-CoA reductase inhibitor); 14 tablets.

• To reduce the risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke, arterial revascularization) in adults at increased risk.DailyMed (NLM)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, to slow progression of atherosclerosis in adults, and in heterozygous (>=8 years) and homozygous (>=7 years) familial hypercholesterolemia.DailyMed (NLM)
• Adjunct to diet for adults with primary dysbetalipoproteinemia or hypertriglyceridemia.DailyMed (NLM)

• Most frequent (>=2%): headache, nausea, myalgia, asthenia and constipation.International label, equivalent formulation · DailyMed (NLM)

• Acute liver failure or decompensated cirrhosis; hypersensitivity to rosuvastatin or any excipient (rash, pruritus, urticaria, angioedema reported).International label, equivalent formulation · DailyMed (NLM)

• Myopathy and rhabdomyolysis: risk factors include age >=65, uncontrolled hypothyroidism, renal impairment, certain concomitant drugs and higher doses; Asian patients may be at higher risk; discontinue if markedly elevated CK or myopathy; patients should report unexplained muscle pain, tenderness or weakness.International label, equivalent formulation · DailyMed (NLM)
• Immune-mediated necrotizing myopathy (rare): discontinue if suspected. Hepatic dysfunction: transaminase increases and rare hepatic failure; consider liver enzyme testing before therapy and as clinically indicated; stop promptly if serious liver injury. Increases in HbA1c and fasting glucose; proteinuria and hematuria reported.International label, equivalent formulation · DailyMed (NLM)

• CyclosporineRosuvastatin exposure increased 7-fold; do not exceed 5 mg once daily.DailyMed (NLM)
• Darolutamide; vadadustatIncreased rosuvastatin exposure; do not exceed 5 mg once daily.DailyMed (NLM)
• GemfibrozilAvoid concomitant use (increased myopathy/rhabdomyolysis risk).DailyMed (NLM)

• Discontinue when pregnancy is recognized (or consider the ongoing therapeutic needs of the individual patient); rosuvastatin may cause fetal harm based on its mechanism, and treatment of hypercholesterolemia is not generally necessary during pregnancy.International label, equivalent formulation · DailyMed (NLM)
• Limited case reports indicate rosuvastatin is present in human milk; no information on effects on the breastfed infant or milk production.International label, equivalent formulation · DailyMed (NLM)

• Rosuvastatin: Inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor), increasing hepatic LDL-receptor expression and LDL-C uptake.